Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06864351 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Evaluation of OptiThyDose

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: University Children's Hospital Basel to University Children's Hospital Basel
    • Trial sites expanded: 2 → 7 locations
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2025 to Aug 28, 2025
    • Site details revised at 2 of 2 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves' disease (GD).
Trial Details
NCT Number NCT06864351
Lead Sponsor University Children's Hospital Basel
Conditions
(from sponsor)		 Thyroid Diseases, Congenital Hypothyroidism, Graves Disease
Related terms Congenital Hypothyroidism, Graves Disease, Thyroid Diseases
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov